This feature highlights changes in clinical research organizations’ personnel.
Neil McFarlane was named chief executive officer at Adamas Pharmaceuticals. McFarlane most recently was chief operating officer at Retrophin.
AIM ImmunoTech has appointed Ellen Lintal chief financial officer. Lintal was previously senior vice president of finance and control for Hemispherx BioPharma, Inc.
Aradhana Sarin has been named chief financial officer at Alexion Pharmaceuticals. Sarin most recently served as chief strategy and business officer at Alexion.
Almirall has appointed Mike McClellan chief financial officer. McClellan is currently group CFO at Teva in Tel Aviv, Israel, and will accept the new position Nov. 11.
Daniella Foster has been named head of public affairs and sustainability for the consumer health division at Bayer. Foster led Global Corporate Responsibility at the Hilton Corporation.
Quentin Blackford was named chief operating officer in addition to his role as chief financial officer at Dexcom. Previously, Blackford was the executive vice president and CFO at the company since 2017.
Andrew Stober has been appointed chief manufacturing officer and David McNinch has been named chief business officer at Encoded Therapeutics. Stober was a leader in gene therapy manufacturing for Novartis and McNinch was a consultant with Encoded Therapeutics.
Jason Brown has been named chief business officer, Frank Grams has been named senior vice president of alliance management and head of business development in Europe, Sophia Zhu has been named senior vice president of portfolio management and strategic planning, Alex Wang has been named head of international business and Daniel Weng has been named vice president of finance at Everest Medicines. Brown founded the company and previously served as senior vice president of business development at Everest. Grams previously served as vice president and global head of alliance management for general medicines and emerging markets and global head of research and development alliance management at Sanofi. Zhu joined Everest from Sanofi China, where she was head of strategic portfolio development and specialty care. Wang was previously general manager of Abbott’s Singapore-based point of care division in the Asia Pacific. Weng previously served as head of finance for Amgen China.
Foghorn Therapeutics has named Samuel Argesta chief medical officer and Allan Reine chief financial officer. Previously, Argesta served as CMO at Infinity Pharmaceuticals and Reine served as CFO at Pieris Pharmaceuticals.
Gemini Therapeutics has named Jason Meyenburg chief executive officer. Meyenburg joined Gemini from Orchard Therapeutics where he was chief commercial officer.
Insitro has added to its leadership with Matthew Rasmussen named vice president of data engineering. Rasmussen most recently served as vice president of software engineering at Myriad Genetics.
Lyra Therapeutics has appointed Vineeta Belanger senior vice president of clinical affairs. Belanger held the position of vice president of clinical affairs at Avedro.
Oystein Rekdal has been named chief executive officer at Lytix Biopharma. Previously, Rekdal served as head of research and development at Lytix Biopharma.
Sean Markey has been named chief business officer and Jennifer Butler has been named chief marketing officer at Medisafe. Markey previously was head of business development at Phreesia and Butler led marketing at New Century Health.
Medispend has named Diana Borges as vice president of compliance solutions and Francoise Renaud as vice president of client operations. Borges was previously director of corporate compliance for Merz North America and Renaud served as program manager for Nuance.
Florence, Italy-based Menarini Group, named Elcin Ergun chief executive officer. Ergun most recently served as executive vice president and head of new businesses at Merck.
Aziz Mottiwala has been named chief commercial officer at Opiant. Mottiwala most recent appointment was with Avanir Pharmaceuticals as senior vice president and head of commercial.
PhRMA has named Lori Reilly the company’s first chief operating officer. Previously, Reilly served as executive vice president of policy, research and membership at PhRMA in her 20 years with the company.
Douglas Sheridan has been named research and development leader at Rallybio. Sheridan was the executive director and global program team leader at Alexion Pharmaceuticals.
Regenix has named Robert Wasserman chief medical officer. Previously, Wasserman served as chairman of the clinical biomarker leadership team and the global head of oncology translational medicine and early clinical development for Roche Pharma.
Salarius Pharmaceuticals has appointed Scott Jordan as chief business officer and Mark Rosenblum at executive vice president finance and interim chief financial officer. Previously, Jordan was the chief financial officer at Salarius since 2016, and Rosenblum was a financial consultant assisting in the recent merger of Flex Pharma at Salarius.
Solgenix has named Daniel Ring president of business development and strategic planning. Ring most recently served as vice president of business development at Exela Pharma Sciences, LLC.
Allen Poirson has been named senior vice president of biopharmaceutical business development. Poirson was previously a partner with Mighty Capital, a venture capital firm.
WindMIL Therapeutics has named Urvashi Patel vice president of regulatory and quality systems. Patel was previously senior director of regulatory affairs at Precision for Medicine.
Worldwide Clinical Trials has named Aman Khera global head of regulatory strategy for the scientific solutions team. Khera was most recently the head of Americas for the regulatory strategy and agency liaison team with PRA Health Services.
Renato Skerlj has been named senior vice president of research and development at X4 Pharmaceuticals. Skerlj previously served as a leader in drug development and discovery at Lysosmal Therapeutics.
Xenon Pharmaceuticals has appointed Shelley McCloskey senior vice president of human resources. Previously, McCloskey was vice president of human resources and administration at Aquniox Pharmaceuticals.